Zacks Research Comments on OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Investment analysts at Zacks Research issued their FY2027 earnings estimates for OPKO Health in a research report issued on Thursday, March 20th. Zacks Research analyst R. Department expects that the biotechnology company will earn ($0.09) per share for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Wednesday, March 19th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th.

OPKO Health Price Performance

OPK opened at $1.81 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company’s 50-day simple moving average is $1.66 and its two-hundred day simple moving average is $1.57. OPKO Health has a 52-week low of $0.92 and a 52-week high of $2.04. The stock has a market capitalization of $1.22 billion, a P/E ratio of -9.53 and a beta of 1.70.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in OPKO Health during the third quarter worth approximately $190,000. FMR LLC boosted its stake in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the period. BNP Paribas Financial Markets increased its position in OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 217,450 shares during the last quarter. Rubric Capital Management LP raised its stake in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares during the period. Finally, Verition Fund Management LLC purchased a new position in shares of OPKO Health during the 3rd quarter worth about $201,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $1.74 per share, with a total value of $348,000.00. Following the acquisition, the chief executive officer now directly owns 213,501,448 shares of the company’s stock, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders bought 964,971 shares of company stock valued at $1,493,692. 47.26% of the stock is owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.